Whalesbook
Year-on-Year Profit Surge Driven by Premium Growth
Star Health and Allied Insurance reported a significant jump in net profit year-on-year for the fourth quarter of fiscal year 2026, reaching ₹111.3 crore. This marks a substantial recovery from the ₹50 lakh profit recorded in the same period last year. The profit growth was supported by a 13.9% rise in net earned premiums to ₹4,327.2 crore. Underwriting losses narrowed to ₹154.28 crore from ₹275.17 crore a year earlier. Operating performance also improved, moving from a ₹87 crore loss to a ₹64 crore profit.
Quarter-on-Quarter Decline and Underwriting Pressure
Despite the strong year-on-year figures, the company's profit fell from ₹128.2 crore in the third quarter of FY26. This sequential drop suggests the large annual gain was partly due to an exceptionally low profit base in Q4 FY25. The continued presence of underwriting losses, though narrowed, indicates ongoing challenges in core insurance operations, where claims and expenses still exceed premiums earned.
Sector Context and Valuation Concerns
The Indian health insurance sector showed strong growth, expanding by 15% in FY26 driven by demand and tax changes. Star Health's premium growth aligned with this positive sector trend. However, Star Health's valuation appears stretched. Its Price-to-Earnings (P/E) ratio of around 67.9x is substantially higher than the Asian industry average of 11.6x. For comparison, ICICI Lombard General Insurance reported a 7.3% year-on-year increase in Profit After Tax (PAT) to ₹5.47 billion in Q4 FY26, with its Gross Direct Premium Income (GDPI) growing by 18.2%. HDFC Life Insurance, meanwhile, saw its net profit rise by a more modest 4% YoY. Star Health's current P/E ratio suggests that the market has already priced in substantial future growth, making the stock susceptible to corrections if growth falters.
Market Reaction and Historical Performance
The company's stock closed only slightly higher at ₹516.35 on Tuesday, April 28, 2026. This muted reaction to strong year-on-year profit numbers highlights investor caution, likely due to the sequential profit decline and the elevated valuation. Historically, the stock has faced investor sentiment challenges, trading down significantly from its IPO price in previous periods.
Analyst Views and Future Outlook
Analysts remain largely positive, with a consensus 'Buy' rating and an average 12-month price target suggesting potential upside. Forecasts predict strong earnings growth, with EPS expected to rise by 35.4% per annum over the next three years, outpacing the Indian market. However, this optimism must be balanced against the current high valuation and the company's need to consistently achieve sequential profit growth and maintain a combined ratio below 100%.